Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cost of Revenue for 4 consecutive years, with $760000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Cost of Revenue rose 16.56% to $760000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 50.96% decrease, with the full-year FY2024 number at $3.0 million, up 7.65% from a year prior.
  • Cost of Revenue was $760000.0 for Q1 2025 at Whitehawk Therapeutics, down from $790000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $927000.0 in Q4 2023 to a low of $179000.0 in Q1 2022.
  • A 4-year average of $609846.2 and a median of $656000.0 in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 317.57% in 2023, then fell 14.78% in 2024.
  • Whitehawk Therapeutics' Cost of Revenue stood at $222000.0 in 2022, then skyrocketed by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then dropped by 3.8% to $760000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cost of Revenue are $760000.0 (Q1 2025), $790000.0 (Q4 2024), and $804000.0 (Q3 2024).